![Research Paper Identification of the key genes and ... · therapeutic target for AML [8, 9]. FLT3 inhibitors have approved for clinical use for mutant FLT3-positive AML in Japan and/or](https://static.fdocuments.in/doc/165x107/5fad545f0815d610c667be84/research-paper-identification-of-the-key-genes-and-therapeutic-target-for-aml.jpg)
FLT3 D835Y
1
P1 FLT3 D835Y P2 ASXL1 G642fs* NF1 intron 2 NPM1c L287Fs* (insTCTG) DNMT3A R882C KRAS K117N TET2 L1119* P3 CEBPA T310NT NRAS G12D P5 IDH1 R132H NPM1c L287fs* (insTCTG) FLT3 D835Y P6 ASXL1 C594* P7 DNMT3A G590fs* IDH2 R172K TET2 P612fs* KRAS G12V P4 NPM1c L287fs* (insTCTG) IDH2 R 140Q WT1 R145fs* CEBPA A111fs* P3 Supplementary Figure S2. Confirmation by capillary sequencing of 21 substitutions and indels identified by targeted pull-down. Chromatographs from AML samples P1-P7 (upper) are contrasted with normal DNA (lower). Arrows indicate substitutions and arrowhead
-
Upload
brielle-schmidt -
Category
Documents
-
view
50 -
download
0
description
NPM1 c L287Fs* (insTCTG). FLT3 D835Y. DNMT3A R882C. P1. NF1 intron 2. ASXL1 G642fs*. KRAS K117N. TET2 L1119*. P2. CEBPA T310NT. CEBPA A111fs*. NRAS G12D. WT1 R145fs*. P3. P3. NPM1c L287fs* (insTCTG). IDH2 R 140Q. P4. NPM1c L287fs* (insTCTG). IDH1 R132H. FLT3 D835Y. P5. - PowerPoint PPT Presentation
Transcript of FLT3 D835Y
P1
FLT3 D835Y
P2
ASXL1 G642fs* NF1 intron 2
NPM1c L287Fs* (insTCTG) DNMT3A R882C
KRAS K117NTET2 L1119*
P3
CEBPA T310NT NRAS G12D
P5
IDH1 R132HNPM1c L287fs*
(insTCTG) FLT3 D835Y
P6
ASXL1 C594*
P7
DNMT3A G590fs* IDH2 R172K
TET2 P612fs* KRAS G12V
P4
NPM1c L287fs*(insTCTG) IDH2 R 140Q
WT1 R145fs* CEBPA A111fs*
P3
Supplementary Figure S2. Confirmation by capillary sequencing of 21 substitutions and indels identified by targeted pull-down. Chromatographs from AML samples P1-P7 (upper) are contrasted with normal DNA (lower). Arrows indicate substitutions and arrowhead indicate indels.
